MISSISSAUGA, Ontario--(BUSINESS WIRE)--
Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV), an advanced medical technologies company, today announced that it will be exhibiting its advanced wound care line up of products at the 5th World Congress of the World Union of Wound Healing Societies (“WUWHS”) to be held in Florence from the 25th to the 29th of September. In addition to exhibiting, a total of 3 clinical and scientific posters will be presented at WUWHS which will highlight the clinical performance of several of the Company's proprietary products.
“The WUWHS event brings together the thought leaders from almost every wound healing society around the world as a captive audience for Covalon to showcase our impressive product portfolio,” said Brian Pedlar, Chief Executive Officer of Covalon. “In addition to the opportunity for our team to interface one on one with an incredible collection of wound care clinicians, compelling clinical and scientific studies that highlight the clinical advantages of our ColActive Plus product line that was recently selected as the exclusive advanced collagen dressing for Saudi Arabian Ministry of Health facilities are being presented.”
WUWHS serves as a highly innovative and valuable event for medical professionals at all levels: physicians, nurses and all those who work in contact with skin wounds on a daily basis. WUWHS 2016 offers an extensive scientific program including numerous symposia, training sessions, workshops and focus sessions with leading international experts in the field of wound management.
“With Covalon’s ever expanding penetration into international markets, WUWHS is a great congress for us to reach key opinion leaders from more than 40 countries” said John R. Hands, Executive Vice President. “From our CovaWound brand of advanced wound management dressings to our patented ColActive bio-matrix technology designed to heal chronic wounds on limbs that may otherwise face amputation, Covalon’s products are gaining global recognition as a better alternative to the legacy brands historically used by advanced wound care clinicians.”
Covalon offers unique, patent protected infection management and advanced wound management solutions for the wound clinician. Covalon’s CovaWound™ and ColActive® brands when used together have the ability to rapidly promote wound closure and healing in both acute and chronic wounds, which has been referred to by experts as major threat to public health and the economy.1
Visit the Covalon Technologies Ltd. booth #61 from September 25-29 at the Fortezza da Basso Congress Center, Florence, Italy.
About Covalon
Covalon Technologies Ltd. researches, develops and commercializes new healthcare technologies that help save lives around the world. Covalon's patented technologies, products and services address the advanced healthcare needs of medical device companies, healthcare providers and individual consumers. Covalon's technologies are used to prevent, detect and manage medical conditions in specialty areas such as wound care, tissue repair, infection control, disease management, medical device coatings and biocompatibility. To learn more about Covalon, visit our website at www.covalon.com
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This news release contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements are often, but not always, identified by the use of words such as "seek", "anticipate", "plan, "estimate", "expect", "intend" and statements that an event or result "may", "will", "should", "could" or "might" occur or be achieved and other similar expressions. These forward-looking statements involve risk and uncertainties, including the difficulty in predicting product approvals, acceptance of and demands for new products, the impact of the products and pricing strategies of competitors, delays in developing and launching new products, the regulatory environment, fluctuations in operating results and other risks, any of which could cause results, performance, or achievements to differ materially from the results discussed or implied in the forward-looking statements. Many risks are inherent in the industry; others are more specific to the Company. Investors should consult the Company's ongoing quarterly filings for additional information on risks and uncertainties relating to these forward-looking statements. Investors should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update or alter any forward-looking statements whether as a result of new information, further events or otherwise.
1 Sen, C. K., Gordillo, G. M., Roy, S., Kirsner, R., Lambert, L., Hunt, T. K., Gottrup, F., Gurtner, G. C. and Longaker, M. T. (2009), Human skin wounds: A major and snowballing threat to public health and the economy. Wound Repair and Regeneration, 17: 763–771. doi:10.1111/j.1524-475X.2009.00543.x
View source version on businesswire.com: http://www.businesswire.com/news/home/20160926005125/en/
